Announcement on Making Provisions for Asset Impairment for 2025
Filed with SSE · · 3 pages · Chinese
Summary by 6ix AI
The board confirmed that the announcement contains no false statements or misleading information. The company conducted a thorough assessment of its assets and determined the need for impairment provisions based on accounting standards. The total impact of these provisions on the company's consolidated profit for the year is reported.
Written in English by 6ix AI from the company’s Chinese-language filing. How 6ix writes summaries
Jiangsu Cowin Biotech Co., Ltd. on 6ix
Earlier from Jiangsu Cowin Biotech
- Announcement on Listing and Circulation of Partial Restricted Shares in Initial Public Offering
- Announcement on Voluntary Disclosure of the Receipt of Class III Medical Device Registration Certificates for Nine Respiratory Pathogen Nucleic Acid Detection Kits (Fluorescent PCR Method)
- Announcement on Preliminary Earnings Estimate for 2025
- Announcement on Change of Sponsor Representative for Continuous Supervision
- Announcement on Retirement and Resignation of Internal Audit Heads
Later from Jiangsu Cowin Biotech
- Report for Q1 2026
- Announcement on Result of Some Directors and Senior Management Members Failing to Reduce Shareholding upon Expiration of the Lock-up Period
- Announcement on Voluntary Disclosure of the Receipt of Class III Medical Device Registration Certificates for Six Respiratory Pathogen Nucleic Acid Detection Kits (Fluorescent PCR Method)
- Announcement on Resolutions of the 2025 Annual General Meeting
- Announcement on Voluntary Disclosure of Obtaining the Class III Medical Device Registration Certificate for the Clostridioides difficile Glutamate Dehydrogenase Antigen and Toxin Detection Kit (Enzyme-Linked Immunochromatographic Assay)
Follow Jiangsu Cowin Biotech into a list and get an email when it puts out news.
Follow Jiangsu Cowin Biotech